Clorazepate Dipotassium Tablets Recalled for Tablet Discoloration Defects Nationwide
Aurobindo Pharma USA Inc. is recalling 6909 bottles of Clorazepate Dipotassium 7.5 mg tablets due to visible discoloration with yellow and dotted spots. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This FDA Class II recall involves a visible quality defect with no reported illnesses or injuries. The discoloration is a manufacturing or packaging defect that warrants a precautionary recall, meeting the moderate severity threshold.
Plain-English summary
Aurobindo Pharma USA Inc. is recalling Clorazepate Dipotassium Tablets, USP, 7.5 mg, manufactured in India and distributed nationwide. The recall involves 6909 bottles in 100-tablet and 500-tablet package sizes with lot numbers CZB124001B, CZB124002B, CZB124003B (100-tablet bottles, expiration 12/31/2025) and CZB124001A, CZB124003A (500-tablet bottles, expiration 12/31/2025). The product is distributed by Aurobindo Pharma USA, Inc., East Windsor, NJ.
The tablets have been identified with visible discoloration, manifesting as dotted and yellow spots. The recall notice does not provide information about the cause of the discoloration or its impact on drug safety or effectiveness.
Consumers with affected bottles should not use them and should return the product to their pharmacy or to Aurobindo Pharma USA Inc. At the time of this recall, no illnesses or injuries have been reported.
The recalled product
- Product
- CLORAZEPATE DIPOTASSIUM (CLORAZEPATE DIPOTASSIUM)
- Brand
- CLORAZEPATE DIPOTASSIUM
- Manufacturer
- Aurobindo Pharma USA Inc.
- Category
- Drug
- Hazard
- discoloration
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #s: a) CZB124001B
- CZB124002B
- CZB124003B
- Exp. 12/31/2025
- b) CZB124001A
- CZB124003A
- Exp. 12/31/2025.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CLORAZEPATE DIPOTASSIUM
- LowClorazepate Dipotassium Tablets Recalled Due to Cosmetic Discoloration
FDA (Drugs) · 2024-05-15
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27